Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novimmune has signed an international research collaboration agreement with Baxalta Incorporated to develop novel bispecific antibodies for an unspecified indication.
Subscribe to our email newsletter
Financial terms of the deal were not disclosed.
This is the first collaboration utilizing Novimmune’s new kappa-lambda bispecific antibody technology. The proprietary platform generates fully human antibodies which target two specific binding sites with one antibody.
Novimmune CEO Jack Barbut said: "The kappa-lambda platform is exactly the right technology for therapy areas which need a bispecific antibody that is as close to a natural human antibody as you can get.
Bispecific antibodies currently used in biopharmaceutical applications have been constructed using chemical linkers, non-human material, antibody fragments or forced engineering, he said.
Head of Research Nicolas Fischer said: "Our kappa-lambda antibodies are allowed to assemble naturally.
"So, they have promising development and safety characteristics such as a longer half-life, increased stability and a lower risk of provoking an unwanted reaction in patients."